Treatment Outcomes Among Patients With a Positive Candida Culture Close to Randomization Receiving Rezafungin or Caspofungin in the ReSTORE Study
Clinical Infectious Diseases · 2024
DOI: 10.1093/cid/ciae363 ↗Kurz gefasst
Randomisierte kontrollierte Studie in der Zeitschrift Clinical Infectious Diseases, 2024. Verfasst von Alex Soriano und 16 weiteren Autor:innen. Beteiligte Einrichtung: Hospital Clínic de Barcelona, IDIBAPS, University of Barcelona, Barcelona, Spain. Hauptthemen laut MEDLINE: Caspofungin, Echinocandins, Antifungal Agents, Candidemia. Die Arbeit wurde bisher 6-mal zitiert (Crossref) und nennt 34 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Cidara Therapeutics, Mundipharma.
Abstract (Originalsprache)
Background
Rezafungin, a novel, once-weekly echinocandin for the treatment of candidemia and/or invasive candidiasis (IC) was noninferior to caspofungin for day 30 all-cause mortality (ACM) and day 14 global cure in the phase 3 ReSTORE trial (NCT03667690). We conducted preplanned subgroup analyses for patients with a positive culture close to randomization in ReSTORE.
Methods
ReSTORE was a multicenter, double-blind, double-dummy, randomized trial in patients aged ≥18 years with candidemia and/or IC treated with once-weekly intravenous rezafungin (400 mg/200 mg) or once-daily intravenous caspofungin (70 mg/50 mg). This analysis comprised patients with a positive blood culture drawn between 12 hours before and 72 hours after randomization or a positive culture from another normally sterile site sampled between 48 hours before and 72 hours after randomization. Efficacy endpoints included day 30 ACM, day 14 global cure rate, and day 5 and 14 mycological response. Adverse events were evaluated.
Results
This analysis included 38 patients randomized to rezafungin and 46 to caspofungin. In the rezafungin and caspofungin groups, respectively, day 30 ACM was 26.3% and 21.7% (between-group difference [95% confidence interval], 4.6% [−13.7%, 23.5%]), day 14 global response was 55.3% and 50.0% (between-group difference, 5.3% [−16.1%, 26.0%]), and day 5 mycological eradication was 71.1% and 50.0% (between-group difference, 21.1% [−0.2%, 40.2%]). Safety was comparable between treatments.
Conclusions
These findings support the efficacy and safety of rezafungin compared with caspofungin for the treatment of candidemia and/or IC in patients with a positive culture close to randomization, with potential early treatment benefits for rezafungin.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Hospital Clínic de Barcelona, IDIBAPS, University of Barcelona, Barcelona, Spain.
- CIBERINF, CIBER of Infectious Diseases, Madrid, Spain.
- CHU UCL Godinne Namur, UCL Louvain Medical School, Campus Godinne, Namur, Belgium.
- Faculty of Medicine Institute of Translational Research, Cologne Excellence Cluster on Cellular Stress Responses in Aging-Associated Diseases (CECAD), University of Cologne, Cologne, Germany.
- Department I of Internal Medicine, Excellence Center for Medical Mycology (ECMM) and German Center for Infection Research (DZIF), Partner Site Bonn-Cologne, University Hospital Cologne, Cologne, Germany.
- Division of Infectious Diseases and Tropical Medicine, Department of Medicine, Faculty of Medicine Siriraj Hospital, Mahidol University, Bangkok, Thailand.
ORCID-Profile: Alex Soriano, Patrick M Honore, Oliver A Cornely, Methee Chayakulkeeree, Huang Haihui, Hervé Dupont, Young Keun Kim, Bart Jan Kullberg, Nick Manamley, Cecilia Dignani, Jose A Vazquez, George R Thompson
Förderung
- Cidara Therapeutics
- Mundipharma
Zitieren
APA
Soriano, A., Honore, P. M., Cornely, O. A., Chayakulkeeree, M., Bassetti, M., Haihui, H., Dupont, H., Kim, Y. K., Kollef, M., Kullberg, B. J., Manamley, N., Pappas, P., Pullman, J., Sandison, T., Dignani, C., Vazquez, J. A., & Thompson, G. R. (2024). Treatment Outcomes Among Patients With a Positive Candida Culture Close to Randomization Receiving Rezafungin or Caspofungin in the ReSTORE Study. Clinical Infectious Diseases. https://doi.org/10.1093/cid/ciae363
Vancouver
Soriano A, Honore PM, Cornely OA, Chayakulkeeree M, Bassetti M, Haihui H, et al. Treatment Outcomes Among Patients With a Positive Candida Culture Close to Randomization Receiving Rezafungin or Caspofungin in the ReSTORE Study. Clinical Infectious Diseases. 2024. doi:10.1093/cid/ciae363
BibTeX
@article{Soriano2024,
author = {Soriano, Alex and Honore, Patrick M and Cornely, Oliver A and Chayakulkeeree, Methee and Bassetti, Matteo and Haihui, Huang and Dupont, Hervé and Kim, Young Keun and Kollef, Marin and Kullberg, Bart Jan and Manamley, Nick and Pappas, Peter and Pullman, John and Sandison, Taylor and Dignani, Cecilia and Vazquez, Jose A and Thompson, George R},
title = {Treatment Outcomes Among Patients With a Positive Candida Culture Close to Randomization Receiving Rezafungin or Caspofungin in the ReSTORE Study},
journal = {Clinical Infectious Diseases},
year = {2024},
doi = {10.1093/cid/ciae363}
}
EUVIMED